Match!
Parambir S. Dulai
University of California, San Diego
188Publications
20H-index
1,736Citations
Publications 192
Newest
Source
Background: Treatment targets for ulcerative colitis are evolving towards achievement of endoscopic improvement and remission in addition to symptom resolution. It remains to be accurately quantified what proportion of patients with symptom resolution have residual endoscopic activity that might warrant treatment modification. Aim: To quantify the prevalence of endoscopic improvement and remission amongst ulcerative colitis patients with various permutations of patient-reported outcomes. Methods...
Source
Source
#1David Faleck (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 5
#2Adam Winters (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 5
Last.Ryan C. Ungaro (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 11
view all 34 authors...
Background & Aims Patients with Crohn's disease (CD), but not ulcerative colitis (UC), of shorter duration have higher rates of response to tumor necrosis factor (TNF) antagonists than patients with longer disease duration. Little is known about the association between disease duration and response to other biologic agents. We aimed to evaluate response of patients with CD or UC to vedolizumab, stratified by disease duration. Methods We analyzed data from a retrospective, multicenter, consortium...
3 CitationsSource
Abstract Background & Aims Non-invasive tests to measure endoscopic activity in patients with Crohn’s disease (CD) have limitations. We aimed to develop a test to identify patients in remission, based on endoscopic analysis, and monitor CD activity based on serum levels of proteins. Methods We developed a test to measure 13 proteins in blood (ANG1, ANG2, CRP, SAA1, IL7, EMMPRIN, MMP1, MMP2, MMP3, MMP9, TGFA, CEACAM1, and VCAM1), called the endoscopic healing index [EHI] using samples from 278 pa...
Source
#1Berkeley N. Limketkai (Stanford University)H-Index: 12
#2Siddharth Singh (UCSD: University of California, San Diego)H-Index: 39
Last.Parambir S. Dulai (UCSD: University of California, San Diego)H-Index: 20
view all 5 authors...
Source
#1Jenna L. Koliani-Pace (Dartmouth–Hitchcock Medical Center)H-Index: 5
#2Siddharth Singh (UCSD: University of California, San Diego)H-Index: 39
Last.Parambir S. Dulai (UCSD: University of California, San Diego)H-Index: 20
view all 35 authors...
Source
#1Robert Battat (UCSD: University of California, San Diego)H-Index: 11
#2Parambir S. Dulai (UCSD: University of California, San Diego)H-Index: 20
Last.Niels Vande Casteele (UCSD: University of California, San Diego)H-Index: 24
view all 4 authors...
ABSTRACTVedolizumab is a monoclonal antibody to the α4β7 integrin that selectively reduces intestinal lymphocyte trafficking, thereby providing a safe and effective treatment option for patients wi...
Source
Source
Source
12345678910